Fentanyl-Xylazine Co-Administration Leads to Sustained Depression of Breathing and Body Temperature Likely Driven by μ-Opioid and α 2 -Adrenergic Pathway Interactions.

BACKGROUND AND PURPOSE: It's been reported that illicit drug supplies increasingly contain the α 2 -adrenergic agonist, xylazine, alongside fentanyl, yet the pharmacological basis for the greater lethality of this combination remains unclear. Prior research has shown that μ-opioid (Oprm1) receptors, on which fentanyl acts, and α 2 -adrenergic (Adra2a) receptors, on which xylazine acts, are both expressed within brainstem circuits that govern autonomic control, especially the parabrachial (PB) and Kölliker-Fuse (KF) nuclei that regulate respiration. Thus, we propose that co-activation of these inhibitory receptors and their respective pathways could potentiate or additively suppress respiratory and thermoregulatory function.

EXPERIMENTAL APPROACH: Freely behaving C57BL/6J mice received intraperitoneal injections of either saline, fentanyl, xylazine, or fentanyl-xylazine (F+X) solutions. Continuous recordings of respiration using whole-body plethysmography, sleep/wake state using EEG/EMG and body temperature using both infrared thermography, and telemetry were collected for several hours following injection. RNAscope was used to identify Oprm1 and Adra2a expression within PB and KF nuclei.

RESULTS: Fentanyl alone produced dose-dependent respiratory depression that was not associated with body temperature changes, whereas the dose we used of xylazine alone had no effect on either respiration or body temperature. In contrast, F+X induced a markedly prolonged (>5 h) reduction in respiratory rate and profound hypothermia lasting 7-8 h, exceeding the effects of either drug alone. Mortality increased to 58.8% following F+X exposure. RNAscope revealed that both Oprm1 and Adra2a receptors are expressed in PB/KF FoxP2-positive neurons, identifying a plausible substrate for convergent inhibitory signaling.

IMPLICATIONS: This manuscript provides the first direct experimental evidence that fentanyl and xylazine may interact through convergent μ-opioid and α 2 -adrenergic receptor signaling to produce additive and sustained suppression of respiratory and thermoregulatory function. These findings address a critical mechanistic gap in understanding the disproportionate lethality of fentanyl-xylazine mixtures, an emerging public-health crisis. The work further identifies the PB/KF FoxP2 population as a plausible site of dual-receptor convergence and highlights a previously unrecognized pharmacodynamic interaction with immediate implications for overdose reversal strategies. Given the novelty, mechanistic insight, and translational urgency of these results, rapid dissemination will help accelerate scientific and clinical responses to this evolving threat.